X-linked retinitis pigmentosa (XLRP)

Clinical trials for X-linked retinitis pigmentosa (XLRP) explained in plain language.

Never miss a new study

Get alerted when new X-linked retinitis pigmentosa (XLRP) trials appear

Sign up with your email to follow new studies for X-linked retinitis pigmentosa (XLRP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Gene therapy shot into both eyes aims to save sight in rare blindness

Disease control Ongoing

This study tests a gene therapy called laruparetigene zovaparvovec (AGTC-501) in 10 males aged 12-50 with X-linked retinitis pigmentosa, a genetic condition that leads to vision loss. The therapy is injected into both eyes to deliver a working copy of the RPGR gene. The main goal…

Matched conditions: X-LINKED RETINITIS PIGMENTOSA (XLRP)

Phase 2 • Sponsor: Beacon Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 14:02 UTC

X-linked retinitis pigmentosa (XLRP)

Get alerted when new X-linked retinitis pigmentosa (XLRP) trials appear

Gene therapy shot into both eyes aims to save sight in rare blindness